DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
Rockville, MD 20857

NDA 12-885/S-037

Ovation Pharmaceuticals
Attention: To, Cunniff, Pharm. D.
Vice President, U.S. Regulatory Affairs
4 Parkway North
Deerfield, IL 60015

Dear Mr. Cunniff:

Please refer to your supplemental new drug application dated August 21, 2002, received August 22, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Winstrol® (stanozolol) Tablets.

We also refer to the amendment dated April 18, 2003, received April 21, 2003, and October 24, 2003, received October 27, 2003, submitted in response to the February 26, 2003, approvable letter. This supplemental new drug application provides for geriatric labeling.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the minor editorial revisions listed below.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 12-885/S-037." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Valerie Jimenez, Regulatory Project Manager, at (301) 827-9090.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff

11/17/03 05:01:59 PM